A Single-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of Various Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia
Latest Information Update: 24 Feb 2022
At a glance
- Drugs Dalosirvat (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors Biosplice Therapeutics; Samumed
- 08 Mar 2016 Results (n = 29) presented at the 74th Annual Meeting of the American Academy of Dermatology.
- 23 Nov 2015 Results presented at the 9th World Congress for Hair Research (WCHR) in Miami, as per Samumed media release.
- 18 Nov 2015 According to a Samumed media release, results from this trial will be presented at the 9th World Congress for Hair Research (WCHR).